GSK Acquires Nuvalent for $10.6 Billion to Expand Lung Cancer Pipeline

GSK Expands Its Reach with Major Acquisition

In a transformative move for the pharmaceutical sector, U.K.-based GSK has announced its decision to acquire U.S. drugmaker Nuvalent for a staggering $10.6 billion. This acquisition, marking GSK's largest in over a decade, is poised to significantly enhance the British company's portfolio, particularly in the lung cancer therapeutic market.

Details of the Acquisition

The all-cash deal values Nuvalent at approximately $124 per share, reflecting a generous 40% premium over its last closing price. According to a filing, the transaction, first reported by the Financial Times, underscores GSK's shift towards bolstering its pipeline amid increasing competition within the pharmaceutical industry.

GSK's CEO, Luke Miels, expressed optimism regarding the acquisition, highlighting that it will facilitate immediate sales growth opportunities and improve profit contributions starting in 2027. "This acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027," Miels stated.

A Strategy Shift for GSK

The decision to pursue such a large acquisition deviates from GSK's previous strategy, which primarily focused on smaller transactions. Earlier this year, Miels emphasized a plan to seek deals within the £2 billion to £4 billion range. This new direction comes as GSK seeks to rejuvenate investor confidence amid scrutiny over its drug pipeline.

Since Miels' appointment, GSK's share price has surged by approximately 29%, reflecting a positive market response to the leadership change and strategic reassessments.

Nuvalent's Promising Therapies

Nuvalent's lead therapy, neladalkib, has garnered significant attention and is currently under FDA review, with a decision scheduled for November 27. In addition, the company is seeking approval for zidesamtinib, targeting ROS1-positive non-small cell lung cancer patients. Analysts at CGS International project that, upon approval, these therapies could generate combined annual revenues of around $823 million by the financial year 2029.

Market Trends and Future Implications

This acquisition arrives amidst a notable frenzy of biotech deal-making, driven by imminent patent expirations and a rebound in public markets. With global biotech deals reaching $106 billion so far in 2026, this trend highlights the increasing urgency among pharmaceutical giants to enhance their pipelines.

GSK's acquisition of Nuvalent not only reinforces its commitment to lung cancer treatment but also positions the company strategically for future growth in a rapidly evolving market.

As the pharmaceutical landscape continues to shift, industry stakeholders will be watching closely to see how this significant acquisition impacts GSK's trajectory and its ability to address critical health needs in oncology.